GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.
| 
                               
                            
                                
                                                                Synonyms: MEDI2452 | PB2452
                                 
                                                         
                            Compound class: 
                                                            Antibody
                                 
                                
                                    
                                        Comment: Bentracimab (formerly PB2452, MEDI2452) is a antibody-derived biologic (a Fab only construct) that is designed to bind and reverse the anti-platelet effects of the P2Y12 receptor antagonist ticagrelor [3-4].
                                    
                                 
                            
                            
                          
                                
                                    
                                
                          
                                   
                                   
                                  
                                    
                                    
                                     | 
                                    
| References | 
| 
                                                                         1. Bhatt DL, Pollack CV, Weitz JI, Jennings LK, Xu S, Arnold SE, Umstead BR, Mays MC, Lee JS. (2019)
                                         Antibody-Based Ticagrelor Reversal Agent in Healthy Volunteers. N Engl J Med, 380 (19): 1825-1833. [PMID:30883047]  | 
                                                                
| 
                                                                         2. Buchanan A, Newton P, Pehrsson S, Inghardt T, Antonsson T, Svensson P, Sjögren T, Öster L, Janefeldt A, Sandinge AS et al.. (2015)
                                         Structural and functional characterization of a specific antidote for ticagrelor. Blood, 125 (22): 3484-90. [PMID:25788700]  | 
                                                                
| 
                                                                         3. Cave B, Rawal A, Ardeshna D, Ibebuogu UN, Sai-Sudhakar CB, Khouzam RN. (2019)
                                         Targeting ticagrelor: a novel therapy for emergency reversal. Ann Transl Med, 7 (17): 410. [PMID:31660309]  | 
                                                                
| 
                                                                         4. Ortega-Paz L, Giordano S, Franchi F, Rollini F, Pollack Jr CV, Bhatt DL, Angiolillo DJ. (2023)
                                         Clinical and Pre-Clinical Pharmacokinetics and Pharmacodynamics of Bentracimab. Clin Pharmacokinet, 62 (5): 673-692. [PMID:37118383]  |